-+ 0.00%
-+ 0.00%
-+ 0.00%

According to the Zhitong Finance App, Quanxin Bio-B (02509.HK) announced that on December 8, 2025, the company received a milestone payment of 5 million US dollars from partner Caldera Therapeutics, Inc. (Caldera). The payment was triggered by QX030N/CLD-423* obtaining an ethics license from the Human Research Ethics Committee (HREC) Phase I clinical trial ethics committee (HREC).

Zhitongcaijing·12/09/2025 11:25:06
Listen to the news
According to the Zhitong Finance App, Quanxin Bio-B (02509.HK) announced that on December 8, 2025, the company received a milestone payment of 5 million US dollars from partner Caldera Therapeutics, Inc. (Caldera). The payment was triggered by QX030N/CLD-423* obtaining an ethics license from the Human Research Ethics Committee (HREC) Phase I clinical trial ethics committee (HREC).